comparemela.com

Latest Breaking News On - Age company profile - Page 1 : comparemela.com

Critical Analysis: InnovAge (OTCMKTS:INNV) vs Sema4 (NASDAQ:SMFR)

InnovAge (OTCMKTS:INNV – Get Rating) and Sema4 (NASDAQ:SMFR – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Volatility & Risk InnovAge has a beta of 1.51, meaning that […]

NewAge, Inc (NASDAQ:NBEV) Expected to Post Quarterly Sales of $110 79 Million

InnovAge Holding Corp (OTCMKTS:INNV) Receives Average Rating of Hold from Analysts

Shares of InnovAge Holding Corp. (OTCMKTS:INNV – Get Rating) have earned a consensus rating of “Hold” from the nine brokerages that are covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month price […]

Critical Review: InnovAge (OTCMKTS:INNV) vs P3 Health Partners (NASDAQ:PIII)

InnovAge (OTCMKTS:INNV – Get Rating) and P3 Health Partners (NASDAQ:PIII – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Profitability This table compares InnovAge and P3 Health Partners’ […]

NewAge, Inc (NASDAQ:NBEV) Expected to Post Earnings of -$0 07 Per Share

Analysts predict that NewAge, Inc. (NASDAQ:NBEV – Get Rating) will post earnings per share (EPS) of ($0.07) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for NewAge’s earnings, with estimates ranging from ($0.12) to ($0.03). NewAge reported earnings of ($0.03) per share during the same quarter last year, which indicates […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.